Sign In
Buy ACCD
$7.02
+0 (+0%)
At Close: Jul 07, 2025
Down -31.39% in 4 Weeks, Here's Why Accolade (ACCD) Looks Ripe for a Turnaround
11:27am, Thursday, 02'nd Nov 2023
Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
1 Market-Beating Stock to Buy Near Its 52-Week High
09:30am, Thursday, 19'th Oct 2023
Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.
Here's Why Accolade (ACCD) is Poised for a Turnaround After Losing -36.43% in 4 Weeks
11:17am, Monday, 09'th Oct 2023
Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Why Shares of Accolade Fell This Week
11:31am, Friday, 06'th Oct 2023
While Accolade increased revenue year over year, it is still losing money. Several analysts downgraded their price targets for the stock.
Accolade, Inc. (ACCD) Q2 2024 Earnings Call Transcript
07:53pm, Wednesday, 04'th Oct 2023
Accolade, Inc. (NASDAQ:ACCD ) Q2 2024 Earnings Conference Call October 4, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Vice President, Investor Relations Rajeev Singh - Chief Executive
Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates
06:47pm, Wednesday, 04'th Oct 2023
Accolade (ACCD) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.66 per share a year ago.
Accolade: Consider Both Growth And Profitability
05:44am, Tuesday, 03'rd Oct 2023
Accolade is in a good position to meet its revenue growth guidance for both the current fiscal year and long term. There is a risk that ACCD's bottom line could fall short of expectations in subsequen
Accolade to Announce Fiscal Second Quarter 2024 Financial Results
08:00am, Wednesday, 20'th Sep 2023
SEATTLE, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal second quarter 2024 finan
CORRECTING and REPLACING -- Accolade To Present at Upcoming Investor Conferences
02:08pm, Wednesday, 06'th Sep 2023
SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Sept. 5, 2023 by Accolade, Inc. (NASDAQ: ACCD), please note that in the second bullet, the time of the Morgan
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:00am, Friday, 01'st Sep 2023
Cathie Wood bought shares of Palantir, Intellia Therapeutics, and Accolade on Thursday. Palantir was downgraded by a prominent analyst on Thursday, and it recently posted its weakest quarterly revenue
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
09:37am, Wednesday, 30'th Aug 2023
Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.
Accolade: Leveraging Tech To Deliver Accessible Healthcare
12:15am, Saturday, 22'nd Jul 2023
Accolade is experiencing strong demand due to rising healthcare costs and employers seeking ways to reduce expenses. The company's proprietary technology platform and health assistants provide persona
Accolade: Growth Reacceleration In FY25 Should Drive Valuation Upside
03:56pm, Thursday, 20'th Jul 2023
I maintain a buy rating for ACCD as I expect growth reacceleration in FY25 which will drive valuation upwards. ACCD's management has raised revenue expectations for FY24 and reiterated long-term reven
Accolade: A Rising Personalized AI-Powered Healthcare Platform
07:00am, Tuesday, 11'th Jul 2023
Accolade Inc. NASDAQ: ACCD is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people manage
Why Accolade Stock Popped by Almost 7% Today
06:42pm, Friday, 30'th Jun 2023
The specialty healthcare solutions provider unveiled its latest set of quarterly results. These handily beat analyst estimates on both the top and bottom lines.
